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An 11 year old, hispanic girl with a history of B-cell acute lymphoblastic leukemia was
admitted to the hospital for symptoms compatible with Bartonella henselae infection. The
ﬁrst molecularly diagnosed case of disseminated Bartonella henselae infection was re-
ported in an immunocompromised patient in Lima, Peru. The analysis was conﬁrmed by
Polymerase Chain Reaction and automated sequencing of a liver biopsy sample, even
though the serologic tests were negative. In conclusion, Bartonella spp. infection should
have a particular diagnostic consideration in immunocompromised patients with fever of
unknown origin and further investigation regarding the patient's past exposures with cats
should also be elicited.1. Introduction
Bartonella spp. is a genus that includes facultative, intra-
cellular, gram-negative bacteria with the potential to cause
prolonged intraerythrocytic bacteremia in mammals [1]. Analysis
of the 16 s rRNA gene has allowed a phylogenetic
reorganization of the genus identifying between 30 and 40
species [2,3]. The main species pathogenic to humans are
Bartonella henselae (B. henselae), Bartonella quintana and
Bartonella bacilliformis (B. bacilliformis), all of which are
etiologies to a series of diseases such as Cat's Scratch Disease,Trench Fever, Chronic Lymphadenopathy, Endocarditis,
Hepatic Peliosis and Carrion's disease [4].
We report an unusual presentation of Bartonella spp. infec-
tion with hepatic, splenic and renal involvement, diagnosed by
PCR in a seronegative immunocompromised patient.
2. Case report
An 11 year old, hispanic girl with a history of B-cell acute
lymphoblastic leukemia (B-ALL) came to the emergency depart-
ment with a history of hyporexia, asthenia, nausea, vomiting, fever
and myalgias that had begun 2 weeks earlier. The patient did not
report any abdominal pain and neither rashes nor lymphadenopa-
thies were evidenced during the exam. The patient's hometown is
Tingo Maria in Huanuco, a rural central region in Peru. Her
household had access to basic services and her family reported they
had two cats, a dog, a hamster and a parrot at home.Amonth before
presentation, the patient received induction chemotherapy IA for
B-cell acute lymphoblastic leukemia with Cytarabine, Dexameth-
asone and Methotrexate; however, the induction IB was delayed
due to a septicemia by positive Klebsiella pneumonia ESBL.rticle under the CC BY-NC-ND license (http://
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catheter. She did not appear under distress and did not appear
toxic. Further examination revealed an axillary temperature of
38.2 C, blood pressure 110/65 mmHg, a heart rate 120 bpm.
Examination of the lungs, heart and abdomen were normal. No
lymphadenopathies, skin rashes or hepatosplenomegaly were
evident.
A complete blood count evidenced leukocytosis with
22.21 × 103 cells/mL and 90% neutrophils. She had a hemo-
globin of 9.5 g/dL and her platelets were at 299 × 103. C-reactive
protein was elevated at 13.46 mg/dL. Her liver function tests,
creatinine and urea were within normal limits.
Blood and urine cultures were repeatedly negative during the
patient's hospital stay. Blood samples cultured for fungi, and
Tuberculosis were negative. Cultures from the Port catheter were
ordered, but came back negative. Moreover, serologic tests for
Cryptococcus neoformans, Histoplasma capsulatum, TORCH,
Hepatitis B virus, HIV and B. henselae were also negative.
An abdominal Computerized tomography (CT) was ordered
revealing hypodense lesions in the liver, spleen and kidneys
(Figure 1A, C, E). The lesions in the liver measured 3.3 cm in
segment VI and 2.1 cm in segment VIII as opposed to the diffuse
distribution of the lesions found in the spleen and kidney thatFigure 1. Computer tomography before and after the treatment.
Transverse view showing nodular hypodensities measuring between 9 and 16 m
The largest hypodensity is seen in the liver measuring 33 mm (black arrow,
treatment (B, D, F). The hepatic lesion decreased in size (F).measured between 0.9 cm and 1.6 cm. The CT also revealed
bilateral axillary adenopathies.
A liver biopsy was ordered and the results showed a ﬁliform
distortion with a complete disruption of the architecture
composed of cicatricial tissue with both an acute and chronic
inﬂammatory process. The liver samples were histochemically
stained with Gram, Ziehl–Neelsen, Giemsa and periodic acid
Schiff, all of which came back with negative results.
The biopsy specimen was sent to the Molecular Laboratory at
the Institute of Nutritional Research in Lima–Peru for a mo-
lecular study. DNA was extracted from the sample and the 16S
rRNA gene from Bartonella spp. was ampliﬁed following the
conditions described by del Valle et al [13]. The results were
positive and the diagnosis of disseminated Bartonella spp.
infection was established (Figure 2). Henceforth, the antibiotic
treatment with Vancomycin, Meropenem and Caspofungin,
initiated based on a clinical suspicion of bacteremia or fungemia,
was suspended and replaced with a daily course of
Azithromycin.
The patient's clinical condition improved gradually with the
new antibiotic regimen. The fever decreased and the patient no
longer reported myalgias, nausea or vomiting, even though
hyporexia persisted. A follow-up Abdominal CT scan wasm in the spleen and kidneys (A with red arrows, and C with white arrow).
E). Most of the lesions in the spleen and kidneys remitted 2 months after
Figure 2. Conventional PCR of 16S Bartonella spp. for the patient's
sample.
The ampliﬁed product is 438 base pairs (bp). (1) Molecular weight marker.
(2) Negative control. (3) Positive control. (4) Sample.
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thromycin had begun and it showed a signiﬁcant reduction in the
size and number of the lesions in the liver, spleen and kidneys
(Figure 1). The patient continued with a favorable clinical
course. Eventually she was discharged with stable clinical con-
ditions and was later followed up to continue the induction
therapy for LLA-B.
3. Discussion
Bartonella spp. are responsible for a worldwide distribution
of zoonotic infections [5]. The clinical course varies from a self
limited infection by B. Henselae [6], to fatal cases seen in
patients infected by B. bacilliformis where mortality rates can
reach 85% if left untreated [7]. In Peru, the incidence of
B. bacilliformis infection is 12, 7/100 person-years, and it in-
creases to 38/100 person-years in children below the age of 5 [8].
B. henselae infection is also reported and it mainly affects the
population below the age of 21 [9], although no local studies
on prevalence have been published.
The main reservoir for B. henselae is the domestic cat with
asymptomatic bacteremia even though transmission has also
been reported from dogs [10,11]. On the other hand, humans are
the only reservoir for B. quintana and B. bacilliformis [3]. The
transmission for most of the species in the Bartonella genus is
through direct contact or via insect vectors. B. henselae can be
transmitted by a cat's scratch, bite or cat ﬂea [12], as is
suspected for our patient's case due to the history of two
household cats. In contrast, transmission of B. bacilliformis
requires a phlebotomus mosquito of the genus Lutzomyia [12].
Bartonella spp. infects erythrocytes and vascular endothelial
cells by means of a ﬂagellum causing intraerythrocytic
bacteremia [13]. B. henselae aids this process by inhibiting
lysosomal fusion and acidiﬁcation after it has been phagocyted
[12].
Bartonella spp. infections have a more disseminated pre-
sentation in immunocompromised patients as reported in caseswith HIV infection [14], LES [15], oncological diagnoses [16] or
post-transplanted individuals [17–20]. These patients generally
have a dermatologic component with violaceous cutaneous
lesions and a visceral component with bacillary angiomatosis
[21–23]. Furthermore, bacteremia, bacillary peliosis, splenitis
and osteomyelitis can also develop [24,25].
In our case report, the patient had a diagnosis of ALL-B and
her immunity was further suppressed with induction therapy.
This may explain the resulting hepatosplenic and renal
involvement.
The gold standard for the diagnosis of B. Henselae is
serology [26]. Assays for B. Henselae can detect IgM and IgG
and may support the clinical diagnosis. Sensitivities vary
between 14% and 100% for IgG and 2%–50% for IgM
whereas the speciﬁcities are 34%–100% and 86%–100%
respectively [6].
Cross-reactivity with other microorganisms may contribute to
false positives and also, these tests may be inaccurate in
immunocompromised patients due to a diminished antibody
response [27]. The latter may explain the persistent seronegativity
evidenced in our patient. Ampliﬁcation of the 16s rRNA
Bartonella gene via PCR is an alternative molecular diagnostic
test with higher sensitivities and speciﬁcities reported [4]. In
our seronegative patient, this method was essential for the
etiologic diagnosis of Bartonella spp. infection under the
suspicion of fever of unknown origin, and for the consequent
adjustment of treatment suspending unnecessary antibiotics.
IDSA guidelines recommend treatment with Azithromycin for
cat scratch disease affecting skin and soft tissue [28], however
deﬁnite treatment for disseminated Bartonella spp. infection
has not been established [29]. A cohort studied the efﬁciency
certain antibiotics for Cat Scratch disease in immunocompetent
patients [30] but to our knowledge a study evaluating antibiotic
efﬁciency for disseminated Bartonella spp. infection in
immunocompromised patients, has not been published.
Appropriate treatment is paramount in these patients due to the
likelihood of a complicated disseminated infection that may
lead to a critical condition or death.
This study presents the ﬁrst reported case in Peru of molec-
ular identiﬁcation of Bartonella spp. via PCR of a hepatic tissue
specimen from an immunocompromised patient diagnosed with
LLA-B and seronegative on multiple occasions for B. henselae.
In conclusion, Bartonella spp. infection should have a
particular diagnostic consideration in immunocompromised pa-
tients with Fever of Unknown Origin and further investigation
regarding the patient's past exposures with cats should also be
elicited. In this case, the deﬁnitive diagnosis was made by a
molecular technique after serology came back negative, stressing
the importance of PCR in a complicated and rare presentation of
Bartonella spp. infection. Prolonged treatment with Azi-
thromycin alone proved effective in this patient, however there
is a need for consensus on the treatment for immunocompro-
mised patients.
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